

Monday, December 12, 2022

## Oral Presentations at ASH Annual Meeting

Note: All times listed are Central Time

Presentation	Speaker	Time/Location
Spotlight Session: Underrepresented Minorities in Clinical Trials for Hematologic Malignancies: What's the Data on the Data?	Kenneth Anderson, MD, Chair	10:30 - 11:45 am R06-R09
Scientific Program: Cell Free DNA Analysis	Jens Lohr, MD, PhD	10:30 - 11:45 am New Orleans Theater AB
723: Multi-Omic Analysis of 253 Untreated Patients with Waldenström's Macroglobulinemia Reveals Clinically and Genomically Distinct Disease Subtypes and a Model for Disease Progression	Zachary R Hunter, PhD	11:00 am 271-273
783: Long-Term Durable FVIII Expression with Improvements in Bleeding Rates Following AAV-Mediated FVIII Gene Transfer for Hemophilia A: Multiyear Follow-up on the Phase I/II Trial of SPK-8011	Stacy E. Croteau, MD, MMS, Dana-Farber/Boston Children's	11:00 am 220-222
748: ZNF683 (Hobit) Marks a CD8+ T Cell Population Associated with Anti-Tumor Immunity Following Anti-PD-1 Therapy for Richter Syndrome	Erin Parry, MD, PhD	11:15 am La Nouvelle Orleans Ballroom AB
706: TP63 Fusions Drive Enhancer Rewiring, Lymphomagenesis, and Dependence on EZH2	Gongwei Wu, PhD	11:15 am 208-210
859: Identification a Novel Molecular Mechanism Underlying the Anti-CD38-Based Treatment Resistance in Multiple Myeloma Patients	Sophia Adamia, PhD	2:45 pm Hall E
880: Non-Relapse Mortality and Quality of Life with Shared Care after Allogeneic Hematopoietic Cell Transplantation: A Randomized Control Trial	Gregory A. Abel, MD, MPH	3:30 pm 391-392
869: Differences in Single Cells between BCMA-Targeting CAR T-Cell Therapy Responders and Non-Responders Reveals Initial Resistance and Acquired Resistance Are Driven by Different Factors	Mehmet K. Samur, PhD	3:45 pm Great Hall B/C
827: Clonal Hematopoiesis Evolves into Dendritic Cell Neoplasm through the Acquisition of UV Mutations in the Skin	Peter van Galen, PhD, Brigham and Women's	3:45 pm 293-294

Monday, December 12, 2022

887: Increasing COVID-19 Vaccination Rates Amongst Children with Sickle Cell Disease: A Quality Improvement Project	Adam P Yan, MD	3:45 pm New Orleans Theater C
828: BPDCN MYB Fusions Bind Cell Cycle Gene Promoters, Reactivate Self-Renewal in Progenitor Cells and Induce Myeloid/Dendritic Leukemia	Christopher A. G. Booth, PhD	4:00 pm 293-294
937: KLRG1 Depletion Is a Novel Therapeutic Strategy for Patients with Mature T and NK/T-Cell Lymphomas	Bimarzhan Assatova	4:30 pm 391-392
Education Program: Transplant for TP53-Mutated MDS and AML: Because We Can or Because We Should?	Coleman Lindsley, MD, PhD	4:30 - 5:45 pm 343-345
Scientific Program: Metabolic Regulation and Implications for Red Cells	Vijay G. Sankaran, MD, PhD, Dana-Farber/Boston Children's Hospital, Chair	4:30 - 5:45 pm 275-277
Special-Interest Session: Building Real-World Research and Collaborative Practice Networks for Malignant Hematology	Donna S. Neuberg, ScD	4:30 - 6:00 PM 217-219
Special-Interest Session: Impact of Real-World Evidence on Research and Clinical Care: Priorities from ASH RC Data Hub	Adam S. Sperling, MD, PhD	4:30 - 6:00 pm 217-219
926: Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis	Lachelle D. Weeks, MD, PhD	4:45 pm 252-254
939: Choline Kinase a Is Required for Alkylating Agent Resistance in T-Cell Acute Lymphoblastic Leukemia	Anais Barthe, Boston Children's	5:00 pm 391-392
964: Lisoftoclax (APG-2575) Safety and Activity as Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study	Matthew S. Davids, MD, MMSc	5:15 pm 243-245